首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

2126556

生物相似藥研發管線市場分析：依產品類型、服務、技術、應用及地區分類

Biosimilar Pipeline Analysis Market, By Product Type, By Services, By Technology, By Application, By Geography

出版日期: 2026年08月26日 | 出版商:

Coherent Market Insights | 英文 255 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，生物相似藥研發管線分析市場規模將達到 402.5 億美元，到 2033 年將達到 1,207.9 億美元。預計 2026 年至 2033 年的複合年成長率將達到 17%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	402.5億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	17.00%	2033年市場規模預測：	1207.9億美元

該市場正經歷強勁成長，主要受以下因素推動：進入臨床開發的生物相似藥候選藥物數量增加、高價值生物製藥專利到期即將到期、對生物類似藥核准的監管支持力度加大、對價格合理的生物製藥治療方案的需求不斷成長，以及製藥和生物技術公司對其生物類似藥開發平臺的投資增加。

生物相似藥研發管線分析是指從產品類型、臨床開發階段、分析技術、治療應用、監管里程碑、專利到期日、競爭對手研發管線以及商業化機會等角度，系統地評估和追蹤生物相似藥候選產品。這有助於製藥和生物技術公司識別有吸引力的參考生物製藥，評估競爭強度，制定研發計劃，監測監管趨勢，並確定潛在的商業化機會的優先順序。

隨著關鍵治療領域生物製藥壟斷地位即將到期，製藥公司越來越重視收集在研產品資訊。對單株抗體、胰島素、胜肽藥物、干擾素和人體生長荷爾蒙相似藥的在研產品評估尤其重要。層析法、質譜法、電泳法、生物生物檢測法、重組DNA技術和西方印漬術等分析表徵技術在證明生物相似藥候選藥物與參考藥物的等效性方面也發揮關鍵作用。

此外，旨在簡化生物相似藥開發要求和減少不必要臨床證據收集的監管措施也在推動市場發展。監管機構日益重視高分析等效性和基於科學的開發路徑，這有望提高開發效率，並鼓勵更多公司參與生物相似藥開發專案。

市場動態

由於越來越多的生物製藥專利到期或失去獨佔權，市場呈現強勁的成長動能。製藥和生技公司正日益重視對生物製藥產品組合的評估，以尋找具有商業性吸引力的生物相似藥候選產品。產品線分析有助於企業評估專利有效性、競爭密度、臨床階段候選藥物、區域研發活動、監管進展以及未來市場機會。根據這份文件，預計到2032年，歐洲將有約100種生物製藥失去獨佔權，但目前其中約79%的生物製藥尚無正在研發的生物類似藥，凸顯了未來產品線拓展的巨大空間。

監管支持的擴大也推動了市場發展。監管機構正日益明確生物相似藥的研發路徑，並促進生物製藥市場的競爭。預計到2025年，美國FDA將核准18種生物相似藥，分別針對10種參考產品，顯示臨床和監管活動持續保持強勁勢頭。隨著監管程序的簡化，持續的研發管線監測、監管資訊收集、研發階段基準分析以及競爭對手評估的重要性日益凸顯。

單株抗體生物相似藥日益成長的商業性重要性也是市場成長的促進因素之一。用於治療癌症和自體免疫疾病的高附加價值生物製藥在生物相似藥研發活動中備受關注。在針對Denosumab、Ustekinumab、Bevacizumab單抗、利Rituximab和Pertuzumab等參考藥物的研發項目的支持下，預計到2026年，單株抗體將佔約46.5%的市場佔有率。

隨著監管機構越來越重視證明生物相似藥與參考生技藥品之間的高度相似性，對先進分析技術的需求也不斷成長。層析法、電泳法、質譜法、生物生物檢測、重組DNA技術、核磁共振和蛋白質印跡西方印漬術等技術可用於理化表徵、純度評估、雜質分析、結構評估和對比分析測試。

臨床開發活動仍然是市場的重要組成部分。藥物動力學、免疫抗原性、安全性、療效比較和醫療設備使用等方面的研究持續為生物類似藥開發項目提供支持，因為僅靠分析證據無法解決剩餘的不確定性。預計到2026年，臨床試驗部分將佔服務類別的約61.0%。

從區域來看，由於歐洲擁有成熟的法規環境、生物相似藥的廣泛應用、支付主導的替代製劑以及完善的研發生態系統，預計歐洲仍將保持領先市場地位。到2026年，歐洲預計將佔全球市場佔有率的約38.5%，而亞太地區預計將在整個預測期內實現最快成長，這主要得益於生物類似藥產能的擴張、監管改革以及中國、印度、韓國和日本的積極研發活動。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了生物相似藥研發管線分析市場中的主要公司概況：公司概況、產品系列、主要亮點、財務績效和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
《生物相似藥研發管線分析市場》報告的目標受眾是該行業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用生物相似藥研發管線分析市場分析中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第9章競爭情勢

熱圖分析
市佔率分析
公司簡介
- Biocon
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Amgen Inc.
- Kyowa Pharmaceutical Industry Co. Ltd
- Boehringer Ingelheim GmbH
- AstraZeneca
- Novartis AG
- Merck & Co
分析師意見

第10章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI582

Biosimilar Pipeline Analysis Market is estimated to be valued at USD 40.25 Bn in 2026 and is expected to reach USD 120.79 Bn by 2033, growing at a compound annual growth rate (CAGR) of 17% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 40.25 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	17.00%	2033 Value Projection:	USD 120.79 Bn

The market is witnessing strong growth primarily driven by the increasing number of biosimilar candidates entering clinical development, upcoming patent expirations of high-value biologic therapies, growing regulatory support for biosimilar approvals, rising demand for affordable biologic treatment options, and increasing investments by pharmaceutical and biotechnology companies in biosimilar development pipelines.

Biosimilar pipeline analysis involves the systematic assessment and tracking of biosimilar candidates across product types, clinical development stages, analytical technologies, therapeutic applications, regulatory milestones, patent expiries, competitive pipelines, and commercialization opportunities. It supports pharmaceutical and biotechnology companies in identifying attractive reference biologics, evaluating competitive intensity, assessing development timelines, monitoring regulatory developments, and prioritizing potential commercialization opportunities.

Pharmaceutical companies are increasingly focusing on pipeline intelligence as biologic medicines approach loss of exclusivity across major therapeutic categories. Pipeline assessment has become particularly important for monoclonal antibodies, insulin, peptides, interferons, and human growth hormone biosimilars. Analytical characterization technologies such as chromatography, mass spectrometry, electrophoresis, bioassays, recombinant DNA technologies, and Western blotting are also playing an important role in demonstrating comparability between biosimilar candidates and their reference products.

The market is further supported by regulatory initiatives aimed at simplifying biosimilar development requirements and reducing unnecessary clinical evidence generation. Regulatory agencies are increasingly emphasizing advanced analytical comparability and science-based development pathways, which are expected to improve development efficiency and encourage additional companies to enter biosimilar development programs.

Market Dynamics

The market is witnessing significant momentum owing to the growing number of biologic medicines approaching patent expiration and loss of exclusivity. Pharmaceutical and biotechnology companies are increasingly evaluating biologic portfolios to identify commercially attractive biosimilar targets. Pipeline analysis helps companies assess patent timelines, competitive density, clinical-stage candidates, geographic development activity, regulatory progress, and future launch opportunities. The collateral indicates that approximately 100 biologic medicines are expected to lose exclusivity in Europe by 2032, while around 79% currently have no biosimilar in development, highlighting considerable scope for future pipeline expansion.

Growing regulatory support is also strengthening the market. Regulatory authorities are increasingly clarifying biosimilar development pathways and encouraging greater competition in biologic medicines. In 2025, the U.S. FDA approved 18 biosimilars covering 10 reference products, demonstrating continued momentum in clinical and regulatory activity. Regulatory streamlining is increasing the importance of continuous pipeline monitoring, regulatory intelligence, development-stage benchmarking, and competitor assessment.

The increasing commercial importance of monoclonal antibody biosimilars is another major market driver. High-value biologics used in oncology and autoimmune diseases are attracting substantial biosimilar development activity. Monoclonal antibodies are expected to account for approximately 46.5% of the market in 2026, supported by development programs targeting reference products such as denosumab, ustekinumab, bevacizumab, trastuzumab, rituximab, and pertuzumab.

Demand for advanced analytical technologies is also increasing as regulators place greater emphasis on demonstrating high similarity between biosimilars and reference biologics. Chromatography, electrophoresis, mass spectrometry, bioassays, recombinant DNA technologies, nuclear magnetic resonance, and Western blotting support physicochemical characterization, purity assessment, impurity profiling, structural evaluation, and comparative analytical testing.

Clinical development activities remain an important component of the market. Pharmacokinetic, immunogenicity, safety, comparative efficacy, and device-use studies continue to support biosimilar development programs where residual uncertainty cannot be addressed through analytical evidence alone. The clinical trials segment is expected to account for approximately 61.0% of the services category in 2026.

Geographically, Europe is expected to remain the leading market owing to its mature regulatory environment, extensive biosimilar adoption, payer-driven substitution practices, and established development ecosystem. Europe is projected to account for approximately 38.5% of the global market in 2026, while Asia Pacific is expected to witness the fastest growth over the forecast period due to expanding biosimilar manufacturing capacity, regulatory reforms, and strong development activity in China, India, South Korea, and Japan.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Biosimilar Pipeline Analysis Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Biocon, Pfizer Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Kyowa Pharmaceutical Industry Co. Ltd, Boehringer Ingelheim GmbH, AstraZeneca, Novartis AG, and Merck & Co.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Biosimilar Pipeline Analysis Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Biosimilar Pipeline Analysis Market

Market Segmentation

By Product Type (Revenue, USD Bn, 2021-2033)
Human Growth Hormone
Insulin
Interferon
Peptides
Monoclonal antibodies
Others
By Services (Revenue, USD Bn, 2021-2033)
Clinical Trials
Contract Research and Manufacturing
By Technology (Revenue, USD Bn, 2021-2033)
Electrophoresis
Recombinant DNA Technology
Chromatography
Nuclear Magnetic Resonance Technology
Bioassay
Mass Spectrometry
Western Blotting
By Application (Revenue, USD Bn, 2021-2033)
Oncology Disease
Auto immune Disease
Blood Disease
Growth Hormone Deficiencies
Global Biosimilar Pipeline Analysis Market, By Region (Revenue, USD Bn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players
Biocon
Pfizer Inc.
Hoffmann-La Roche Ltd
Amgen Inc.
Kyowa Pharmaceutical Industry Co. Ltd
Boehringer Ingelheim GmbH
AstraZeneca
Novartis AG
Merck & Co

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Services
- Market Snapshot, By Technology
- Market Snapshot, By Application
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Biosimilar Pipeline Analysis Market, By Product Type, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Human Growth Hormone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Interferon
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Peptides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Monoclonal antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Biosimilar Pipeline Analysis Market, By Services, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Clinical Trials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Contract Research and Manufacturing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Biosimilar Pipeline Analysis Market, By Technology, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Electrophoresis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Recombinant DNA Technology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Chromatography
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Nuclear Magnetic Resonance Technology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Bioassay
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Mass Spectrometry
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Western Blotting
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

7. Global Biosimilar Pipeline Analysis Market, By Application, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Oncology Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Auto immune Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Blood Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Growth Hormone Deficiencies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

8. Global Biosimilar Pipeline Analysis Market, By Region, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Services, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Services, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Services, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Services, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Services, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Services, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Biocon
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- F. Hoffmann-La Roche Ltd
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Kyowa Pharmaceutical Industry Co. Ltd
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Boehringer Ingelheim GmbH
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- AstraZeneca
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Merck & Co
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views